Literature DB >> 1577476

An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy.

N J Sharp1, J N Kornegay, S D Van Camp, M H Herbstreith, S L Secore, S Kettle, W Y Hung, C D Constantinou, M J Dykstra, A D Roses.   

Abstract

Golden retriever muscular dystrophy (GRMD) is a spontaneous, X-linked, progressively fatal disease of dogs and is also a homologue of Duchenne muscular dystrophy (DMD). Two-thirds of DMD patients carry detectable deletions in their dystrophin gene. The defect underlying the remaining one-third of DMD patients is undetermined. Analysis of the canine dystrophin gene in normal and GRMD dogs has failed to demonstrate any detectable loss of exons. Here, we have demonstrated a RNA processing error in GRMD that results from a single base change in the 3' consensus splice site of intron 6. The seventh exon is then skipped, which predicts a termination of the dystrophin reading frame within its N-terminal domain in exon 8. This is the first example of dystrophin deficiency caused by a splice-site mutation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577476     DOI: 10.1016/0888-7543(92)90210-j

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  126 in total

1.  Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping.

Authors:  Lawrence T Bish; Meg M Sleeper; Sean C Forbes; Bingjing Wang; Caryn Reynolds; Gretchen E Singletary; Dennis Trafny; Kevin J Morine; Julio Sanmiguel; Sylvain Cecchini; Tamas Virag; Adeline Vulin; Cyriaque Beley; Janet Bogan; James M Wilson; Krista Vandenborne; Joe N Kornegay; Glenn A Walter; Robert M Kotin; Luis Garcia; H Lee Sweeney
Journal:  Mol Ther       Date:  2011-12-06       Impact factor: 11.454

2.  Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.

Authors:  Toshifumi Yokota; Eric Hoffman; Shin'ichi Takeda
Journal:  Methods Mol Biol       Date:  2011

Review 3.  The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

Authors:  Qi-Long Lu; Toshifumi Yokota; Shin'ichi Takeda; Luis Garcia; Francesco Muntoni; Terence Partridge
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

4.  Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.

Authors:  Toshifumi Yokota; Qi-Long Lu; Terence Partridge; Masanori Kobayashi; Akinori Nakamura; Shińichi Takeda; Eric Hoffman
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

Review 5.  Approaching a new age in Duchenne muscular dystrophy treatment.

Authors:  Kathryn R Wagner
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 6.  Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Akinori Nakamura
Journal:  J Hum Genet       Date:  2017-06-01       Impact factor: 3.172

Review 7.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

8.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

10.  Transplantation of Human Adipose Mesenchymal Stem Cells in Non-Immunosuppressed GRMD Dogs is a Safe Procedure.

Authors:  M V Pelatti; J P A Gomes; N M S Vieira; E Cangussu; V Landini; T Andrade; M Sartori; L Petrus; Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.